Income Statement
CRISPR THERAPEUTICS AG
CRSP
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
3.51 | 37.31 | 371.21 | 1.20 | 914.96 | 0.72 | 289.59 | 112.60 | 41.00 | 5.16 |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
3.51 | 37.31 | 371.21 | 1.20 | 914.96 | 0.72 | 289.59 | 112.60 | 41.00 | 5.16 |
|
Operating Expenses
|
668.08 | 503.88 | 593.74 | 674.36 | 541.44 | 355.15 | 242.85 | 162.07 | 105.65 | 73.29 |
|
Research & Development
|
284.81 | 320.65 | 387.33 | 461.65 | 438.63 | 266.95 | 179.36 | 113.77 | 69.80 | 77.40 |
|
Selling, General & Administrative
|
73.54 | 72.98 | 76.16 | 102.46 | 102.80 | 88.21 | 63.49 | 48.29 | 35.85 | 31.06 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-664.57 | -466.57 | -222.54 | -673.16 | 373.53 | -354.44 | 46.74 | -49.47 | -64.65 | -68.13 |
|
Non-Operating Income
|
86.61 | 103.90 | 71.82 | 22.66 | 6.00 | 6.38 | 20.57 | -5.49 | -1.96 | 45.41 |
|
Interest Income
|
- | 104.30 | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
86.61 | 103.90 | 71.82 | 22.66 | 6.00 | 6.38 | -5.47 | -4.28 | -1.76 | -36.53 |
|
Income Before Tax
|
-577.97 | -362.67 | -150.72 | -650.50 | 379.53 | -348.06 | 67.31 | -0.30 | -66.61 | -22.72 |
|
Income Tax Expense
|
3.63 | 3.59 | 2.89 | -0.33 | 1.87 | 0.81 | 0.45 | 0.26 | 1.75 | 0.46 |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | -0.03 |
|
Net Income
|
-581.60 | -366.25 | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 | -164.98 | -68.36 | -23.18 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-645.09 | -447.31 | -202.70 | -648.99 | 391.48 | -345.25 | 51.47 | -45.95 | -61.62 | -67.21 |
|
Earnings Per Share (Basic)
|
-6.47 | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | - | - | - |
|
Diluted EPS
|
-6.47 | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | - | - | - |
|
Weighted Average Shares
|
89.93 | 84.36 | 79.22 | 77.75 | 75.95 | 65.95 | 54.39 | - | - | - |
|
Diluted Weighted Avg Shares
|
89.93 | 84.36 | 79.22 | 77.75 | 80.39 | 65.95 | 56.93 | - | - | - |
|
Comprehensive Income
|
-578.62 | -366.33 | -136.05 | -660.76 | 372.68 | -348.96 | 66.87 | -0.30 | -68.32 | -23.22 |